Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Paradigm Biopharmaceuticals ( (AU:PAR) ) has provided an announcement.
Paradigm Biopharmaceuticals has activated a new clinical trial site in Hong Kong for its global Phase 3 study of injectable pentosan polysulfate sodium in patients with knee osteoarthritis, with screening now underway at the Hong Kong Centre for Clinical Research. The company is also preparing to bring three sites in Moldova online, extending a trial network that already spans Australia and the United States.
The expansion comes as Paradigm nears the 50% recruitment milestone in the 466-patient PARA_OA_012 study, a key trigger for an interim analysis focused on pain reduction at Day 112 and functional outcomes. By adding Hong Kong and Moldova under CRO NBCD alongside existing CRO Advanced Clinical, Paradigm aims to accelerate enrolment, bolster its global data package for future regulatory submissions, and reinforce its position in late-stage osteoarthritis drug development.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.25 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company focused on discovering, developing and delivering pharmaceutical therapies to improve patients’ health and quality of life. The company’s current lead program is injectable pentosan polysulfate sodium (iPPS), an anti-inflammatory and tissue-regenerative candidate being developed for osteoarthritis and other diseases driven by inflammation.
Average Trading Volume: 954,145
Technical Sentiment Signal: Sell
Current Market Cap: A$113.5M
For an in-depth examination of PAR stock, go to TipRanks’ Overview page.